Applied DNA Sciences, Inc. (APDN): Company Cash Volume

Brandmark of Applied DNA Sciences, Inc. (APDN)

Geopolitical tensions are driving demand for DNA markers to secure supply chains, although trade barriers may restrict access to equipment. Applied DNA Sciences (APDN) revenues rely on product authentication and contract synthesis, which necessitates strict cost control. The stability of diagnostics minimizes cyclical impact. Regarding the cash position history, this GURU.Markets chart illustrates liquidity, where 0.01 is recorded as the baseline value.

APDN - Applied DNA Company Cash Reserve over the range 07/04/2022 - 10/07/2025

Metric breakdowns and analytics for Applied DNA Sciences, Inc. (APDN)

- stock quotes and analyst forecast:
Analysis of all company metrics:APDN adnas.com
Brand item of adnas.com

The liquid stability of Applied DNA Sciences (APDN) depends directly on its ability to cover operating expenses amid volatile demand for DNA components. This metric aggregates all available cash reserves ready for immediate allocation. It is critical for investors to monitor this capital as a buffer against cash flow gaps. Additional share issuances often support this balance. Analyzing changes in the cash balance allows for an assessment of the business's actual margin of safety.

Main competitors

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|ocugen.com - Company Cash Volume|PACB - Company Cash Volume|BNTC: Company Cash Volume|Company Cash and Cash Equivalents DSGN|Company Cash Funds Rocket Pharmaceuticals|Company Cash on Hand 4DMT (FDMT)|Company Cash Volume LXEO|Company Liquid Assets Korro Bio Inc.|Company Cash Volume EDIT (Editas Medicine Inc)|SLN: Company Cash and Cash Equivalents|PRQR - Company Cash Funds|Company Liquid Assets codexis.com CDXS|SGMO: Company Cash Volume|Nautilus Biotechnology (NAUT) - Company Cash Volume|Company Cash Funds Metagenomi, Inc|precisionbiosciences.com (DTIL) - Company Liquid Assets|Company Cash Funds Generation Bio Co. (GBIO)|Company Liquid Assets Boundless Bio, Inc.|Company Cash Funds Exicure, Inc. XCUR|IMNN: Company Cash and Cash Equivalents|PHIO - Company Cash Funds|Company Liquid Assets Mustang Bio MBIO|RNAZ: Company Cash Volume|Company Cash Position Bionano Genomics Inc. BNGO|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume